Adage Capital Partners’s Immuneering IMRX Stock Holding History

Adage Capital Partners’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-50,000	Closed	-$145K	–	908
2024 Q1	$145K	Sell	50,000 -50,000	-50%	-$280K	﹤0.01%	823
2023 Q4	$735K	Sell	100,000 -95,000	-49%	-$633K	﹤0.01%	772
2023 Q3	$1.5M	Buy	195,000 +20,000	+11%	+$184K	﹤0.01%	749
2023 Q2	$1.77M	Sell	175,000 -30,000	-15%	-$288K	﹤0.01%	745
2023 Q1	$1.99M	Buy	205,000 +130,000	+173%	+$738K	﹤0.01%	765
2022 Q4	$364K	Hold	75,000	–	–	﹤0.01%	867
2022 Q3	$1.07M	Sell	75,000 -10,000	-12%	-$79.4K	﹤0.01%	888
2022 Q2	$460K	Sell	85,000 -65,000	-43%	-$347K	﹤0.01%	940
2022 Q1	$971K	Sell	150,000 -164,000	-52%	-$1.58M	﹤0.01%	935
2021 Q4	$5.08M	Buy	+314,000	New	+$7.64M	0.01%	815

Other funds holding IMRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Adage Capital Partners's IMRX Position: Q2 2024 in Review

Adage Capital Partners sold out of Immuneering (IMRX) in Q2 2024, closing a stake of 50,000 shares — an estimated $145K sold.

Adage Capital Partners first reported a position in IMRX in Q4 2021 and held it in 10 quarters. The position peaked at $5.08M in Q4 2021. 59 funds tracked by Wall St. Rank hold IMRX as of Q2 2024.

Adage Capital Partners reported no remaining Immuneering position as of Q2 2024 after selling out during the quarter.
Adage Capital Partners sold 50,000 Immuneering shares in Q2 2024, an estimated $145K.
Adage Capital Partners first reported a position in Immuneering in Q4 2021 and held it in 10 quarters.
Adage Capital Partners's Immuneering position peaked at $5.08M in Q4 2021.
59 funds tracked by Wall St. Rank held Immuneering as of Q2 2024.

Based on Adage Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.